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Introduction: To investigate the diagnostic performance of folate 
receptor–positive circulating tumor cells in distinguishing non–
small-cell lung cancer (NSCLC) from lung benign disease by using 
a novel ligand-targeted polymerase chain reaction (PCR) detection 
technique.
Methods: Circulating tumor cells were enriched from 3-ml periph-
eral blood by immunomagnetic depletion of leukocytes and then 
labeled with a conjugate of a tumor-specific ligand folic acid and a 
synthesized oligonucleotide. After washing off free conjugates, the 
stripped bound conjugates were analyzed by quantitative PCR.
Results: Seven hundred fifty-six participants (473 patients with 
NSCLC, 227 patients with lung benign disease, and 56 healthy 
donors) were randomly assigned to a training set and a test set. The 
circulating tumor cell (CTC) levels in patients with NSCLC were 
significant higher than those with lung benign disease (p < 0.001) 
and healthy donors (p < 0.001). Compared with carcinoembryonic 
antigen, neuron-specific enolase, and Cyfra21-1, CTCs displayed the 
highest area under the receiver operating characteristic curve (train-
ing set, 0.815; validation set, 0.813) in the diagnosis of NSCLC, with 
a markedly sensitivity (training set, 72.46%; validation set, 76.37%) 
and specificity (training set, 88.65%; validation set, 82.39%). The 
model combining CTCs with carcinoembryonic antigen, neuron-
specific enolase, and Cyfra21-1 was more effective for the diagno-
sis of NSCLC than tumor makers alone (sensitivity and specificity 
in the training set, 84.21% and 83.91%; validation set, 88.78% and 
87.36%, respectively). In addition, the CTC levels were higher in 
patients with stage III/IV NSCLC compared with those with stage 
I/II disease.
Conclusion: Ligand-targeted PCR technique was feasible and reli-
able for detecting folate receptor–positive CTCs in patients with 
NSCLC, and CTC levels could be used as a useful biomarker for the 
diagnosis of NSCLC.
Key Words: Circulating tumor cells, Non–small-cell lung cancer, 
Folate receptor, Polymerase chain.
(J Thorac Oncol. 2015;10: 1163–1171)
The concept of circulating tumor cells (CTCs) was not a new kid, which has been described a century ago by Paget.1 
Recent advances in technical approaches (i.e., CTC detection, 
enumeration, and characterization) have demonstrated that 
CTCs play an important role in the development of tumor 
metastasis2 and could act as a potential biomarker for early 
cancer detection, diagnosis, evaluation of treatment efficacy, 
and prognosis in several solid tumors.3–10 More recently, the 
potential value of CTC detection as a liquid biopsy has been 
established and become increasingly important, especially in 
those tumors where tissue is not easy to access, such as lung 
cancer. Conversely, the demand for tumor tissue is increasing 
because of the introduction of individual therapy in clinical 
practice. Thus, detection of CTCs may be potentially used to 
establish a diagnosis, as an alternative to invasive biopsies for 
early detection.
Currently, the CellSearch System (Veridex LLC, 
Raritan, NJ) is the first and unique technique that has been 
approved by the U.S. Food and Drug Administration for CTC 
detection and routine use in the clinical setting of breast, 
colorectal, and prostate cancers, but not in lung cancer so 
far. In brief, the CellSearch System is a semiautomated and 
immunomagnetic system for quantitative evaluation of CTCs 
by capturing an immune-bead antigen, epithelial cell adhe-
sion molecule (EpCAM). However, this system is unable to 
detect the CTCs that present with nonepithelial characteris-
tics (EpCAM-negative CTCs). For instance, the epithelial-
to-mesenchymal transition, a common biologic process in 
lung cancer that changes epithelial cells to a mesenchymal 
phenotype, may result in escaping detection by CellSearch 
technique.11–13 Although EpCAM-based CTC-Chip device 
has exhibited an ability to capture large numbers of CTCs,14 
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the reasons similar with CellSearch System limited its further 
use in clinical setting.15 Isolation by size epithelial tumor cells 
(ISET; RareCell Diagnostics) is a nonimmunologic-based, 
EpCAM-independent CTC isolation technique. Krebs et al. 
have demonstrated that ISET could detect higher numbers of 
CTCs including epithelial-negative CTCs in non–small-cell 
lung cancer (NSCLC) compared with CellSearch System.16 
However, ISET may miss cells less than 8 μm in size and 
needs further validation before routine clinical use.17
The folate receptors (FRs), a cell-surface receptor gly-
coprotein, are highly expressed in a variety of cancers, espe-
cially in lung cancer, in which 72% to 83% patients with 
NSCLC overexpress the FR on cell surface.18–20 Previous 
studies have showed promising clinical value of detect-
ing FR-positive CTC by a novel ligand-targeted polymerase 
chain reaction (LT-PCR) method in patients with NSCLC.21,22 
Herein, we conducted this large-scale, prospective, double-
blind clinical trial to evaluate the feasibility of LT-PCR CTC 
detection method in the diagnosis of NSCLC. Furthermore, 
we compared the diagnostic yields between CTCs and tradi-
tional tumor makers (i.e., carcinoembryonic antigen [CEA], 
neuron-specific enolase [NSE], and Cyfra21-1) in patients 
with NSCLC.
PATIENTS AND METHODS
Patients
This was a prospective, single-center clinical trial con-
ducted at Shanghai Pulmonary Hospital, Tongji University, 
China (trial registered number: ChiCTR-DDT-12003034). 
From September 15, 2012, to December 15, 2013, 756 par-
ticipants were enrolled into this study (including 56 [7.4%] 
healthy volunteers, 227 [30%] patients with benign lung 
disease, and 473 [62.6%] patients initially diagnosed with 
NSCLC). The healthy participants also underwent low-dose 
spiral chest computed tomography (CT) scan to exclude the 
potential thoracic disease. Benign lung diseases were pneumo-
nia, pulmonary tuberculosis, bronchiectasis, or pneumothorax 
diagnosed according to the results of thoracic CT scan, labo-
ratory examination, or lung biopsy. The NSCLC patients had 
histologically or cytologically confirmed as adenocarcinoma 
(ADC) or squamous cell carcinoma (SCC) or others (large-
cell carcinoma, no other specific). The clinical staging was 
based on the initial evaluation consisting of clinical assess-
ment, the thoracic and abdomen CT scan, CT or magnetic res-
onance imaging of the brain, and bone scan. The International 
Association for the Study of Lung Cancer 7th Tumor, Node, 
Metastasis Staging System was used for clinical disease stag-
ing. The ethics committees of Shanghai Pulmonary Hospital 
approved the study, and an informed consent was obtained 
from each participant before study entry.
CTC Analysis
CTC analysis was performed using CytoploRare 
method provided by GenoSaber Biotech Co. Ltd. (Shanghai, 
China) as described previously.21,22 Blood sample (3 ml) from 
eligible individuals were collected in vacuum tubes containing 
the anticoagulant ethylenediaminetetraacetic acid for analysis 
after diagnosed before commencing treatment. All peripheral 
blood specimens were stored in 4°C refrigerator, and CTC 
analysis was performed within 24 hours.
In brief, CTCs were enriched by lysis of erythrocytes 
and immunomagnetic depletion of leukocytes (by anti-CD45-
coated magnetic beads) from the blood according to the man-
ufacture’s protocol. Then it was labeled with a conjugate of a 
tumor-specific ligand folic acid and a synthesized oligonucle-
otide as described previously.21,22 After that, the CTCs were 
collected for quantitative PCR analysis. Before amplifica-
tion, the conjugate first annealed and extended on the reverse 
transcriptase primer. After immunofluorescence staining the 
enriched CTCs, CTCs were defined as cells expression folate 
ligands and cytokeratin (8, 18, and 19) and 4′,6-diamidino-
2-phenylindole–stained nucleus. In this study, we used an 
arbitrarily defined CTC unit, which was defined as the num-
ber of CTCs detected in 3 ml of blood. A serial of standards 
containing oligonucleotides (10−14 to 10−9 M, correspond-
ing to 2 to 2 × 105 CTC units/3 ml blood) were used for CTC 
quantification.
To evaluate the recovery ratio in spiked cell assay, we 
used human nasopharyngeal cancer line KB cells that express 
FR on cell surface. To determine the linearity of the assay, the 
observed and spiked CTC count across all the data points were 
analyzed by linear regression, as described previously.21
Analysis of Tumor Makers
Three milliliter anticoagulant blood sample of all 
recruitment patients was collected for analysis of tumor mak-
ers (CEA, NSE, and Cyfra21-1) by enzyme-linked immune 
sandwich assay method (Roche Diagnostics) at the day of 
sample collection.
Statistical Analysis
The datasets were randomly assigned to training set and 
validation set by crossvalidation to confirm gender and age 
matched. First, training set was used to train a classifier. Then, 
the validation set was used to test the model obtained from 
the training set to be used as evaluation of performance of the 
classifier. The differences of CTC units between two groups 
were compared using the Mann-Whitney U test, and among 
three groups or more were compared using the Kruskal-Wallis 
test. Prism 5.0 (GraphPad software Inc., San Diego, CA) and 
MedCalc (version 13.0.0) were used to analyze receiver oper-
ating characteristic (ROC) curves to determine the threshold 
of specificity and sensitivity, and the area under the ROC 
curves (AUCs) were calculated for each index. The Youden 
index was used to identify the optimal cutoff point and diag-
nostic efficiency (when the threshold value for [sensitivity + 
specificity – 1] was maximized).
To identify the best diagnostic biomarkers, ROC and 
corresponding AUCs were calculated for all biomarker and for 
their combinations. We compared the specificity and sensitiv-
ity of joint diagnostic model (CTC in combination with tumor 
marker) with tumor markers only (CEA in combination with 
NSE and Cyfra21-1) by binary logistic regression analysis to 
determine whether CTC could improve the diagnostic accu-
racy. Statistical analysis was performed using SPSS software 
Copyright © 2015 by the International Association for the Study of Lung Cancer
1165Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 8, August 2015 FR-Positive Circulating Tumor Cell
FIGURE 1.  Receiver operating characteristic analysis 
between lung cancer and benign disease and healthy group. 
CTC, circulating tumor cell.
(18.0, SPSS Inc., Chicago, IL). All p values were based on 
two-sided testing, where p values less than 0.05 were consid-
ered significant.
RESULTS
Study Population
The characteristics of the patients in the training and vali-
dation sets are summarized in Table 1. With SPSS randomized 
software, a total of 756 participants were randomly assigned 
to the training set (total 377 participants [236 patients with 
NSCLC, 113 patients with lung benign disease, and 28 health 
donors]) and the validation set (total 379 participants [237 
patients with NSCLC, 114 patients with lung benign disease, 
and 28 healthy donors]). The study groups were well matched 
with respect to baseline characteristics of enrolled patients, 
and exploratory analysis showed that there was no difference 
in patient baseline characteristics between the training set and 
validation set.
CTC Levels in Patients with Lung Cancer 
and Benign Disease and Health Donors
The CTC units were presented as median ± interquar-
tile range. On the basis of the ROC curve, the optimal cutoff 
threshold in differentiating patients with NSCLC from lung 
benign disease was 8.93 units, with a sensitivity of 74.4% and 
specificity of 86.6% (Youden index = 0.61; Fig. 1).
First, we compared the CTC unit levels among the differ-
ent groups (NSCLC versus lung benign disease versus health 
donor; Fig. 2). In the training set, the CTC levels in patients 
with NSCLC (11.64 ± 8.6 units) were significantly higher than 
those with lung benign disease (6.60 ± 5.21 units; p < 0.001) and 
healthy donors (5.72 ± 4.49 units; p < 0.001). While there was 
no notable difference between patients with lung benign disease 
and healthy donors (p = 0.314). In the validation set, the CTC 
TABLE 1.  Patient Characteristics
Training Set Validation Set
Lung Cancer
Controls
Lung Cancer
Controls
Benign Diseases Healthy Controls Benign Diseases Healthy Controls
No. of patients 236 113 28 237 114 28
Age (yr)
Mean (range) 59 (33–82) 49 (15–85) 51 (36–68) 59 (23–83) 49 (18–79) 56 (28–72)
Gender
  Male 162 60 15 161 64 12
  Female 74 53 13 76 50 16
Smoking status
  Former smoker 128 64 19 127 62 17
  Current smoker 108 49 9 110 52 11
Pathology
  ADC 149 144
  SCC 53 50
  Others 34 43
TNM stage
  I 6 12
  II 2 3
  III 66 61
  IV 162 161
ADC, adenocarcinoma; SCC, squamous cell carcinoma; TNM, tumor, node, metastasis.
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levels in patients with NSCLC (12.41 ± 9.02 units) were also sig-
nificantly higher than those with lung benign disease (6.95 ± 5.45 
units; p < 0.001) and healthy donors (5.95 ± 4.57 units; p < 0.001). 
Consistently, there was no significant difference between patients 
with lung benign disease and healthy donors (p = 0.335).
Next, we analyzed the correlation between CTC level 
and the clinical characteristics of patients with NSCLC. 
The CTC levels in patients with stage I and II NSCLC 
(10.17 ± 6.23 units) were significantly lower than those with 
stage III disease (11.96 ± 8.23 units, p = 0.036) and stage IV 
disease (12.44 ± 9.02 units, p = 0.004), whereas there was no 
significant difference between patients with stage III and IV 
NSCLC (p = 0.320; Fig. 2). In addition, we did not observe 
any relation between CTC level and other clinical characteris-
tics, including age (≤60 years versus >60 years), gender (male 
versus female), smoking status (former smoker versus current 
smoker), and pathology (ADC versus SCC and others).
ROC Analyses of CTC Level, CEA, NSE, 
and Cyfra21-1 and the Diagnostic Yield 
of Joint Diagnostic Models for NSCLC
The diagnostic efficiencies of the investigating clini-
cal biomarkers, CTC level, CEA, NSE, and Cyfra21-1, in 
FIGURE 2.  The level of CTC in lung cancer versus benign disease versus healthy donor. CTC, circulating tumor cell.
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distinguishing NSCLC from lung benign disease were com-
pared by plotting ROC curves. The AUCs and 95% confidence 
interval (CI), sensitivity, specificity for CTC, CEA, NSE, and 
Cyfra21-1, and their positive predictive value and negative 
predictive value in the diagnosis of NSCLC are summarized 
in Table 2.
Among the four clinical biomarkers, CTC level dis-
played the highest AUC (training set, 0.815; 95% CI, 0.772–
0.853; validation set, 0.813; 95% CI, 0.770–0.851; Table 2) 
in differentiating patients with NSCLC from lung benign 
disease, with a markedly sensitivity (training set, 72.46%; 
validation set, 76.37%) and specificity (training set, 88.65%; 
validation set, 82.39%). Among the four clinical biomarkers, 
CTC level (training set: AUC, 0.827; 95% CI, 0.775–0.870; 
validation set: AUC, 0.806; 95% CI, 0.752–0.852; Table 2) 
displayed comparable efficacy in differentiating patients with 
ADC from lung benign disease compared with CEA (train-
ing set: AUC, 0.819; 95% CI, 0.761–0.867; validation set: 
AUC, 0.817; 95% CI, 0.758–0.867; Table 2). Among the four 
clinical biomarkers, CTC level (training set: AUC, 0.794; 
95% CI, 0.731–0.847; validation set: AUC, 0.822; 95% CI, 
0.763–0.872; Table 2) displayed comparable efficacy in dif-
ferentiating patients with non-ADC from lung benign disease 
compared with Cyfra21-1 (training set: AUC, 0.796; 95% CI, 
0.727–0.855; validation set: AUC, 0.853; 95% CI, 0.790–
0.903; Table 2).
To improve the diagnostic accuracy, a joint model (CTC 
in combination with tumor marker) and tumor markers model 
(CEA in combination with NSE and Cyfra21-1) for NSCLC 
diagnosis were conducted. Notably, the combination of CTC, 
CEA, NSE, and Cyfra21-1 could significantly improve the 
diagnostic efficacy in differentiating patients with NSCLC, 
ADC, and non-ADC from lung benign disease than tumor 
markers model alone, respectively.
The AUCs of the joint model and tumor markers model for 
NSCLC and benign disease were 0.883 (95% CI, 0.841–0.925) 
and 0.842 (95% CI, 0.794–0.889) in training set and 0.936 
(95% CI, 0.906–0.965) and 0.870 (95% CI, 0.828–0.911; 
p = 0.001) in validation set, respectively. The same difference 
was shown in differentiating patients with ADC from lung 
benign disease (p = 0.007) or patients with non-ADC from 
lung benign disease (p = 0.003; Table 3 and Fig. 3).
DISCUSSION
In this study, we found that CTC levels were signifi-
cantly higher in 473 patients with NSCLC compared with 227 
patients with lung benign disease and 56 healthy donors. CTC 
levels can effectively distinguish lung cancer from nonmalig-
nant lung disease with a consistently high AUC of 0.815 in 
the training set and 0.813 in the validation set, which was sig-
nificantly higher than the combination of plasma tumor mak-
ers (CEA, NSE, and Cyfra21-1). In addition, we also found 
that the diagnostic yield of CTC for NSCLC improved in this 
study when combined with plasma tumor markers.
Recently, several reliable and reproducible techniques to 
isolate, enumerate, and detect CTCs in peripheral blood have 
been established. However, there is still no standard proce-
dure to detect CTCs in clinical practice for NSCLC, and each TA
B
LE
 2
. 
Th
e 
D
ia
gn
os
tic
 E
ffi
ci
en
cy
 o
f C
TC
 in
 D
iff
er
en
tia
tin
g 
Pa
tie
nt
s 
w
ith
 N
SC
LC
 a
nd
 B
en
ig
n 
Pu
lm
on
ar
y 
D
is
ea
se
 a
nd
 H
ea
lth
y 
Pe
op
le
D
ia
gn
os
ti
c 
G
ro
up
T
ra
in
in
g 
Se
t
V
al
id
at
io
n 
Se
t
A
U
C
95
%
 C
I
Se
ns
it
iv
it
y 
(%
)
Sp
ec
ifi
ci
ty
 (
%
)
P
os
it
iv
e 
L
R
N
eg
at
iv
e 
L
R
p
A
U
C
95
%
 C
I
Se
ns
it
iv
it
y 
(%
)
Sp
ec
ifi
ci
ty
 
(%
)
P
os
it
iv
e 
L
R
N
eg
at
iv
e 
L
R
p
A
 a
rm
0.
81
5
0.
77
2–
0.
85
3
72
.4
6
88
.6
5
6.
39
0.
31
<
0.
00
01
0.
81
3
0.
77
0–
0.
85
1
76
.3
7
82
.3
9
4.
34
0.
29
<
0.
00
01
B
 a
rm
0.
81
4
0.
77
0–
0.
85
4
72
.4
6
88
.5
0
6.
30
0.
31
<
0.
00
01
0.
81
2
0.
76
7–
0.
85
2
76
.3
7
81
.5
8
4.
15
0.
29
<
0.
00
01
C
 a
rm
0.
81
8
0.
77
6–
0.
86
2
72
.8
8
89
.2
9
6.
80
0.
30
<
0.
00
01
0.
81
7
0.
76
5–
0.
86
1
78
.4
8
85
.7
1
5.
49
0.
52
<
0.
00
01
D
 a
rm
0.
56
2
0.
47
6–
0.
64
5
71
.6
8
50
.0
0
1.
43
0.
57
0.
33
70
0.
55
9
0.
47
3–
0.
64
2
66
.6
7
53
.5
7
1.
44
0.
62
0.
34
77
A
 a
rm
, N
S
C
L
C
 v
s.
 c
on
tr
ol
s 
(b
en
ig
n 
pu
lm
on
ar
y 
di
se
as
e 
an
d 
he
al
th
y 
pe
op
le
);
 B
 a
rm
, N
S
C
L
C
 v
s.
 b
en
ig
n 
di
se
as
e;
 C
 a
rm
, N
S
C
L
C
 v
s.
 h
ea
lt
hy
 p
eo
pl
e;
 C
I,
 c
on
fi
de
nc
e 
in
te
rv
al
; 
D
 a
rm
, b
en
ig
n 
di
se
as
e 
vs
. h
ea
lt
hy
 p
eo
pl
e;
 N
S
C
L
C
, 
no
n–
sm
al
l-
ce
ll
 lu
ng
 c
an
ce
r.
Copyright © 2015 by the International Association for the Study of Lung Cancer
1168 Copyright © 2015 by the International Association for the Study of Lung Cancer
Chen et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 8, August 2015
TA
B
LE
 3
. 
Th
e 
D
ia
gn
os
tic
 E
ffi
ci
en
cy
 o
f M
od
el
s 
in
 D
iff
er
en
tia
tin
g 
Pa
tie
nt
s 
w
ith
 N
SC
LC
 a
nd
 B
en
ig
n 
Pu
lm
on
ar
y 
D
is
ea
se
T
ra
in
in
g 
Se
t
V
al
id
at
io
n 
Se
t
A
U
C
 (
95
%
C
I)
SN
 (
%
)
SP
 (
%
)
P
P
V
 (
%
)
N
P
V
 (
%
)
A
U
C
 (
95
%
 C
I)
SN
 (
%
)
SP
 (
%
)
P
P
V
 (
%
)
N
P
V
 (
%
)
N
S
C
L
C
 v
s.
 b
en
ig
n 
di
se
as
e
 
 C
T
C
0.
81
5 
(0
.7
72
–0
.8
53
)
72
.4
6
88
.6
5
93
.0
2
60
.6
5
0.
81
3 
(0
.7
70
–0
.8
51
)
76
.3
7
82
.3
9
90
.0
2
65
.6
5
 
 C
E
A
0.
75
6 
(0
.7
03
–0
.8
04
)
52
.8
6
89
.6
6
91
.4
3
47
.6
6
0.
77
1 
(0
.7
19
–0
.8
18
)
61
.4
6
83
.9
1
88
.8
2
51
.1
6
 
 N
S
E
0.
72
4 
(0
.6
70
–0
.7
74
)
50
.2
4
87
.3
6
89
.2
4
45
.6
7
0.
61
2 
(0
.5
54
–0
.6
68
)
32
.0
4
90
.8
0
87
.0
4
38
.9
4
 
 C
yf
ra
21
-1
0.
78
4 
(0
.7
33
–0
.8
30
)
79
.1
5
70
.1
1
84
.6
8
61
.6
9
0.
80
0 
(0
.7
50
–0
.8
45
)
66
.0
2
80
.4
6
87
.5
4
53
.2
5
 
 C
E
A
 +
 N
S
E
 +
 C
yf
ra
21
-1
0.
84
2 
(0
.7
94
–0
.8
89
)
81
.8
2
78
.1
6
88
.6
7
67
.3
1
0.
87
0 
(0
.8
28
–0
.9
11
)
80
.9
8
82
.7
6
90
.7
1
67
.6
7
 
 C
T
C
 +
 C
E
A
+
 N
S
E
 +
 C
yf
ra
21
-1
0.
88
3 
(0
.8
41
–0
.9
25
)a
84
.2
1
83
.9
1
91
.6
1
71
.7
9
0.
93
6 
(0
.9
06
–0
.9
65
)a
88
.7
8
87
.3
6
93
.5
9
78
.9
3
A
D
C
 v
s.
 b
en
ig
n 
di
se
as
e
 
 C
T
C
0.
82
7 
(0
.7
75
–0
.8
70
)
73
.8
3
88
.5
0
89
.4
3
71
.9
5
0.
80
6 
(0
.7
52
–0
.8
52
)
75
.6
9
81
.5
8
83
.8
4
72
.6
6
 
 C
E
A
0.
81
9 
(0
.7
61
–0
.8
67
)
60
.1
5
93
.1
0
92
.0
0
63
.9
2
0.
81
7 
(0
.7
58
–0
.8
67
)
56
.9
1
95
.4
0
93
.9
8
63
.6
8
 
 N
S
E
0.
72
0 
(0
.6
55
–0
.7
78
)
50
.0
0
87
.3
6
83
.9
1
56
.9
9
0.
59
1 
(0
.5
22
–0
.6
58
)
39
.5
2
79
.3
1
70
.6
9
50
.9
4
 
 C
yf
ra
21
-1
0.
77
7 
(0
.7
17
–0
.8
30
)
79
.8
5
70
.1
1
77
.8
9
72
.5
3
0.
76
6 
(0
.7
03
–0
.8
21
)
60
.4
8
80
.4
6
79
.6
3
61
.7
2
 
 C
E
A
 +
 N
S
E
+
 C
yf
ra
21
-1
0.
86
9 
(0
.8
21
–0
.9
16
)
80
.3
0
81
.6
1
85
.2
0
75
.8
6
0.
85
8 
(0
.8
07
–0
.9
09
)
69
.1
1
93
.1
0
92
.6
7
70
.4
7
 
 C
T
C
 +
 C
E
A
+
 N
S
E
 +
 C
yf
ra
21
-1
0.
89
2 
(0
.8
49
–0
.9
34
)
86
.3
6
85
.0
6
88
.4
0
82
.5
5
0.
92
9 
(0
.8
94
–0
.9
65
)a
87
.8
0
88
.5
1
90
.6
1
85
.1
7
N
on
-A
D
C
 v
s.
 b
en
ig
n 
di
se
as
e
 
 C
T
C
0.
79
4 
(0
.7
31
–0
.8
47
)
70
.1
1
88
.5
0
82
.4
4
79
.3
6
0.
82
2 
(0
.7
63
–0
.8
72
)
77
.4
2
81
.5
8
77
.4
2
81
.5
8
 
 C
E
A
0.
64
7 
(0
.5
69
–0
.7
20
)
50
.6
5
74
.7
1
60
.6
6
66
.2
9
0.
70
3 
(0
.6
28
–0
.7
71
)
52
.4
4
83
.9
1
72
.6
7
68
.3
8
 
 N
S
E
0.
73
2 
(0
.6
57
–0
.7
98
)
75
.3
2
64
.3
7
61
.9
4
77
.2
1
0.
64
3 
(0
.5
66
–0
.7
15
)
39
.0
2
90
.8
0
77
.5
8
64
.6
0
 
 C
yf
ra
21
-1
0.
79
6 
(0
.7
27
–0
.8
55
)
72
.7
3
82
.7
6
76
.5
0
79
.7
6
0.
85
3 
(0
.7
90
–0
.9
03
)
60
.9
8
95
.4
0
91
.5
4
74
.9
8
 
 C
E
A
 +
 N
S
E
 +
 C
yf
ra
21
-1
0.
80
9 
(0
.7
39
–0
.8
79
)
75
.3
2
79
.3
1
73
.7
0
80
.6
7
0.
88
9 
(0
.8
39
–0
.9
39
)
69
.5
1
94
.2
5
90
.7
9
79
.1
2
 
 C
T
C
 +
 C
E
A
 +
 N
S
E
 +
 C
yf
ra
21
-1
0.
88
3 
(0
.8
29
–0
.9
38
)a
85
.7
1
82
.7
6
79
.2
9
88
.2
7
0.
95
5 
(0
.9
26
–0
.9
83
)*
95
.1
2
86
.2
1
84
.9
1
95
.5
9
a X
 X
 X
.
A
D
C
, a
de
no
ca
rc
in
om
a;
 A
U
C
, a
re
a 
un
de
r 
th
e 
re
ce
iv
er
 o
pe
ra
ti
ng
 c
ha
ra
ct
er
is
ti
c 
cu
rv
e;
 C
E
A
, c
ar
ci
no
em
br
yo
ni
c 
an
ti
ge
n;
 C
I,
 c
on
fi
de
nc
e 
in
te
rv
al
; C
T
C
, c
ir
cu
la
ti
ng
 tu
m
or
 c
el
l;
 N
P
V,
 n
eg
at
iv
e 
pr
ed
ic
tiv
e 
va
lu
e;
 N
S
E
, n
eu
ro
n-
sp
ec
ifi
c 
en
ol
as
e;
 P
P
V,
 p
os
it
iv
e 
pr
ed
ic
tiv
e 
va
lu
e;
 S
N
, s
en
si
tiv
it
y;
 S
P,
 s
pe
ci
fi
ci
ty
; N
S
C
L
C
, n
on
–s
m
al
l-
ce
ll
 lu
ng
 c
an
ce
r.
Copyright © 2015 by the International Association for the Study of Lung Cancer
1169Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 8, August 2015 FR-Positive Circulating Tumor Cell
technique has its own weakness.23,24 The LT-PCR technique 
used in this study was based on the negative depletion of leu-
kocytes followed by labeling with folate-linked oligonucle-
otide and quantification with quantitative PCR. ROC curve 
analysis identified 8.93 units as the optimal cutoff threshold 
in the diagnosis of NSCLC, with a sensitivity of 74.4% and 
specificity of 86.6%, which is in line with previous stud-
ies.21,22 In a previous study with limited samples by Yu et al.,22 
the cutoff threshold in distinguishing NSCLC from controls 
(healthy donors and lung benign disease) was 8.64 CTC units, 
with a sensitivity of 73.2%, specificity of 84.1%, and AUC of 
0.823. Moreover, the median CTC units in their study were 
5.71, 6.74, and 10.82 in healthy donors, benign diseases, and 
patients with NSCLC, respectively, which was also very simi-
lar with the results of our study. In another small sample study, 
the identified cutoff threshold was 8.5 units.21 Taken together, 
we demonstrated that LT-PCR technique was feasible, reli-
able, and reproducible for quantifying FR-positive CTCs in 
peripheral blood samples from patients with NSCLC.
Currently, majority of technologies just showed their 
ability to monitor CTC in patients with advanced lung can-
cer. For example, Krebs et al.8 found that CTCs detected 
by CellSearch System act as a novel prognostic factor in 
patients with NSCLC; however, positive CTC counts were 
FIGURE 3.  The receiver operating characteristic 
curve of circulating tumor cell in combination with 
tumor marker in pulmonary malignant tumor. 
ADC, adenocarcinoma; NSCLC, non–small-cell lung 
cancer.
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not detected in patients with stage IIIA disease and were 
found only in 32%(19 of 60) of patients with stage IV 
NSCLC in their study. Thus, the enrolled patients mainly 
included patients with advanced NSCLC. Besides that, the 
patients with early-stage (stage I/II disease) NSCLC were 
also included as a small proportion (23 of 473, 4.9%). Our 
study showed that the median CTC of the patients with early-
stage NSCLC were significantly higher than patients with 
lung benign disease, although it is lower than patients with 
advanced NSCLC. Consistent with our results, previous 
study also demonstrated that the FR is a potential surface 
marker in identifying CTC of patients with NSCLC, even in 
early stage,21 which suggest that CTC could also be poten-
tial biomarkers for early diagnosis of lung cancer and pre-
dicting the staging of patients with NSCLC. Notably, Lou 
et al.21 found that the CTC levels were significantly higher 
in EpCAM-negative fraction than in EpCAM-positive frac-
tion in patients with NSCLC when using FR-based detective 
method. As EpCAM-dependent immunologic techniques 
tend to sacrifice sensitivity for the sake of specificity, 
CellSearch System showed an insufficient capability to dis-
tinguish patients with NSCLC from lung benign disease (p 
= 0.122).25 More sensitive and specific analytical methods, 
such as LT-PCR–based method, are urgently needed as alter-
native techniques in clinical practice.
There were controversial reports about the FR expres-
sion of CTCs in different histologic types. In the study by 
Yu et al.,22 the CTC levels in SCC were significantly higher 
than that in ADC (p = 0.038). However, this study included 
a large cohort of 473 patients with NSCLC, and there was 
also no significant difference of FR expression between 
ADC and SCC regarding CTC levels, which was consistent 
with the result of the study by Lou et al.21 Previous stud-
ies demonstrated that the FR expression is much lower in 
SCC than that in ADC in primary tumors,18,19,26 while genes 
expressed differently between primary tumor and CTC sam-
ples may partly explain the discrepant result.27 Importantly, 
these inconsistent findings also raised an intriguing issue in 
clinical practice: Is the difference existed between primary 
tumors and CTCs regarding the driver genes, which has been 
already observed in breast cancer?28 However, several stud-
ies have found that it is feasible to extract genomic DNA and 
perform mutational driver genes analysis such as epidermal 
growth factor receptor and anaplastic lymphoma kinase in 
CTCs in patients with NSCLC.29,30 Thus, CTCs, serving as a 
“liquid biopsy” approach, might be potentially widely used 
in clinical practice in the future.
In addition, we also compared the diagnostic yields of 
CTC with traditional serum tumor marker in this study. As 
we know, serum tumor biomarkers such as CEA, NSE, and 
Cyfra21-1 were frequently used to help diagnose NSCLC in 
clinical practice. However, their sensitivity is still low, ranging 
from only 20% to 70%,31–34 and lack specificity. Our results 
showed that CTC levels detected by LT-PCR–based method 
displayed the highest AUC compared with CEA, NSE, and 
Cyfra21-1 in the diagnosis of NSCLC. Thus, CTC levels could 
act as an effective auxiliary diagnostic marker for NSCLC. 
Furthermore, the diagnostic yield improved when CTC was 
combined with tumor makers in the diagnosis of NSCLC, sug-
gesting that the combined model should be recommended in 
clinical practice in the future.
In conclusion, we found that LT-PCR technique was 
feasible and reliable for detecting FR-positive CTCs in 
patients with NSCLC in this large-scale, prospective clinical 
trial. More importantly, CTC levels could be used as a use-
ful diagnostic biomarker for patients with NSCLC, especially 
in combination with serum tumor markers. Further study to 
investigate the prognostic or “liquid biopsy” value of CTCs 
detected by LT-PCR–based method in patients with NSCLC 
is warranted.
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